Organon & Co (NYSE:OGN) — Market Cap & Net Worth
Market Cap & Net Worth: Organon & Co (OGN)
Organon & Co (NYSE:OGN) has a market capitalization of $3.52 Billion ($3.52 Billion) as of June 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #4540 globally and #1520 in its home market, demonstrating a 0.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Organon & Co's stock price $13.43 by its total outstanding shares 262600862 (262.60 Million). Review how much debt does Organon & Co carry to assess the company's total debt and financial obligations.
Organon & Co Market Cap History: 2021 to 2026
Organon & Co's market capitalization history from 2021 to 2026. Data shows change from $6.83 Billion to $3.53 Billion (-13.36% CAGR).
Index Memberships
Organon & Co is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.23 Trillion | 0.11% | #18 of 24 |
|
S&P Small-Cap 600 Index
SML
|
$1.64 Trillion | 0.26% | #153 of 602 |
Weight: Organon & Co's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Organon & Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Organon & Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.30x
Organon & Co's market cap is 0.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.07x
Organon & Co's market cap is 10.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $6.83 Billion | $6.30 Billion | $1.35 Billion | 1.08x | 5.05x |
| 2022 | $6.50 Billion | $6.17 Billion | $917.00 Million | 1.05x | 7.08x |
| 2023 | $3.56 Billion | $6.26 Billion | $1.02 Billion | 0.57x | 3.48x |
| 2024 | $3.92 Billion | $6.40 Billion | $864.00 Million | 0.61x | 4.53x |
| 2025 | $1.88 Billion | $6.22 Billion | $187.00 Million | 0.30x | 10.07x |
Competitor Companies of OGN by Market Capitalization
Companies near Organon & Co in the global market cap rankings as of June 19, 2026.
Key companies related to Organon & Co by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #27 globally with a market cap of $550.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1098.57 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #27 | Johnson & Johnson | NYSE:JNJ | $550.26 Billion | $228.39 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $216.49 |
Organon & Co Historical Marketcap From 2021 to 2026
Between 2021 and today, Organon & Co's market cap moved from $6.83 Billion to $ 3.53 Billion, with a yearly change of -13.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.53 Billion | +87.31% |
| 2025 | $1.88 Billion | -51.94% |
| 2024 | $3.92 Billion | +9.92% |
| 2023 | $3.56 Billion | -45.12% |
| 2022 | $6.50 Billion | -4.86% |
| 2021 | $6.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Organon & Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.52 Billion USD |
| MoneyControl | $3.52 Billion USD |
| MarketWatch | $3.52 Billion USD |
| marketcap.company | $3.52 Billion USD |
| Reuters | $3.52 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more